The Future of Technology In 2026 and Beyond
Over the past decade, the tech sector has tended to rebound after bouts of underperformance, about 80% of the time, historically. This year looked like another chapter in that same story: short-term skepticism giving way to renewed conviction.
Now, as we move into the final quarter of 2025, several massive forces are quietly re-shaping the landscape.
» Read more about: The Future of Technology In 2026 and Beyond »
Read More
Forget Tesla, This EV Stock Just Got a Billion-Dollar Lifeline
If you’ve spent any time watching the electric vehicle space, chances are you’ve already dug into Tesla. But as Tesla enters its next phase of maturity, investors with an eye for disruption might want to turn their attention to a different name, one that’s flying under the radar but could be setting up for a breakout.
» Read more about: Forget Tesla, This EV Stock Just Got a Billion-Dollar Lifeline »
Read More
Is Archer Aviation the Next Breakout Stock?
Palantir Technologies (NYSE: PLTR) has become one of the most talked-about names in artificial intelligence and not just because of its work with governments and Fortune 500s.
Investors have started to view a Palantir partnership as something of a credibility stamp. So when the company joined forces with a lesser-known player like Archer Aviation (NYSE: ACHR),
» Read more about: Is Archer Aviation the Next Breakout Stock? »
Read More
Nvidia Just Matched Microsoft in Value, So Is It Still a Smart Buy?
Nvidia (NASDAQ: NVDA) just pulled off something extraordinary, again. Fiscal Q1 2026 numbers weren’t just good, they were extraordinary.
Management reported a top line of $44.1 billion, up 69% from the same time last year, and 12% higher than the previous quarter. Net income was an eye-popping $18.8 billion, and that’s in spite of a $4.5 billion charge tied to new U.S.
» Read more about: Nvidia Just Matched Microsoft in Value, So Is It Still a Smart Buy? »
Read More
Pfizer’s Big Win Means What For Investors?
Pfizer just pulled off a big deal as it relates to the pharmaceutical landscape in the U.S. On Tuesday, the CEO announced a wide-ranging agreement with the Trump administration that will lower drug prices for many Americans.
At the center of this deal is a new government-backed portal called “TrumpRx”, a website designed to help patients access discounted prescription drugs by connecting them directly to manufacturers’ platforms.
» Read more about: Pfizer’s Big Win Means What For Investors? »
Read MoreThe Ivy
Will Prediction Markets Disrupt DraftKings?
DraftKings and FanDuel have long dominated U.S. online sports betting, thanks to their early entry via daily fantasy sports.
That first-mover advantage, combined with cutting-edge technology and deep brand recognition, let both companies capture the lion’s share of the market as sports betting rolled out state by state.
But a new kind of competitor is emerging that could rewrite the rules of online wagering.
» Read more about: Will Prediction Markets Disrupt DraftKings? »
Read MoreThe Spotlight
Could Lemonade’s AI Insurance Engine Turn $1 Billion Into $10 Billion
After months of market jitters, earnings season has brought a wave of upbeat results, and stocks tied to improving outlooks are rallying hard.
Many investors who sat on the sidelines during the downturn are now realizing they may have missed some exceptional entry points.
But the best opportunities are about finding businesses with a runway long enough to turn today’s price into tomorrow’s fortune.
» Read more about: Could Lemonade’s AI Insurance Engine Turn $1 Billion Into $10 Billion »
Read MoreThe Daily
Donald Trump calls for larger cuts after Federal Reserve reduces interest rates to 3-year low
JavaScript is disabled in your browser.
Please enable JavaScript to proceed.
A required part of this site couldn’t load. This may be due to a browser
extension, network issues, or browser settings. Please check your
connection,